


REFERENCES



References

Abdel-Aziz F, Habib M, Mohamad MK, et al.

Hepatitis C virus infection in a community in Nile Delta: Population description and HCV prevalence. *Hepatology* 32:111-115(2000).

Abdel- Ghafar Y, Madwar MA Khalil A,et al.

The effect of propranolol on portal hypertension and prevention of recurrent variceal bleeding in schistosomal and non-schistosomal patients. *Afro.J.Liver.*1: 104, (1996).

Abdel-Wahab MF, Zakaria S, Kamel M, et al.

High prevalence of hepatitis C infection among risk groups in Egypt. *Med.Hyg*, 51(50): 563-567, (1994).

Ackerman M,

Pathological diagnosis of chronic hepatitis C. In: Ackerman's Surgical Pathology. Barwick W and Juan Rosal(eds.). The liver, chronic hepatitis. Pp861-925(1996).

Afonso AM, Didier J, Plouvier E, et al.

Performance of an automated system for quantification of hepatitis C virus RNA. *J Virol Methods* 6: 55-60, (2000).

Akahane Y, Kojima M, Sugai Y, et al.

Hepatitis C virus infection in spouses of patients with type C chronic liver disease. *Ann.Intern.Med.*120: 748, (1994).

Akatsuka T, Donets M, Scaglione L, et al.

B cell epitopes on the hepatitis C virus nucleocapsid protein determined by human monospecific antibodies. *Hepatology* 18:503-510, (1993).

Allander T, Beyene A, Jacobson S, et al.

Patients infected with the same hepatitis C virus strain display different kinetics of the isolate- specific antibody response. *J Infect Dis.* 175:26-31, (1997).

Alter MJ,

Transfusion-associated non-A, non-B Hepatitis. The first decade. In: Zuckerman AJ, ed. viral hepatitis and liver disease. New York: liss, 537-

542(1988).

Alter MJ,

Chronic consequences of non-A, non-B hepatitis. In: Seeff LB, Lewis JH, (eds.). Current perspective in hepatology. New York: Plenum Medical Books, Pp: 83-97, (1989).

Alter MJ,

Descartes before the horse: I clone, therefore I am: the hepatitis C virus in current perspective. Ann Intern Med 115:644-649, (1991).

Alter MJ,

Epidemiology of hepatitis C in the west. Semin.Liver Dis.15: 5, (1995).

Alter MJ, Conry-Cantilena C, Melpolder J, et al.

Hepatitis C in asymptomatic blood donors. Hepatology 26 (suppl.1): 29s-33s, (1997).

Alter MJ, Hadlers C, Judson FN, et al.

Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA, 264:2231-5 (1990).

Alter MJ, Kruszon-Moran D, Ninan OV, et al.

The natural history of hepatitis C in the United States. N Engl. J Med 327: 1899-1905, (1992).

Alter MJ, Kruszon-Moran D, Ninan OV, et al.

The prevalence of Hepatitis C virus in the United States, 1988 through 1994. N Engl J Med 327: 1899-1905,(1999).

Alter HJ, and Seeff LB,

Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long- term outcome. Semin Liver Dis 20: 17-35, (2000).

Amaraa R, Mareckova H, Urbanek P, et al.

T helper, cytotoxic T lymphocyte, NK cell and NK-T cell subpopulations in patients with chronic hepatitis C. Folia Microbiol 47(6):717-22(2002).

Ando K, Kaneko T, Hiroishi K, et al:

Perforin, Fas/Fas ligand, and TNF-alpha pathway as specific and bystander killing mechanism of hepatitis C virus specific human CTL. *J Immunol* 158: 5283-5291, (1997).

Angeleco M, Renganon E, Gandin C, et al:

Chronic liver disease in Alexandria governrate, Egypt: contribution of schistosomiasis and hepatitis viral infection. *J.Hepatology*, 26(2): 236-243, (1997).

Angello V,

The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection. *Springer Semin Immunopathol* 19:111-119, (1997).

Archi T, Major M, Wedemeyer H, et al.

Vigorous HCV-helicase specific T helper response dominates in the liver of chimpanzee during acute, self-limited hepatitis C. *Hepatology* 30:453A, (1999).

Bahandari BN, Kim M, Ferrell L, et al.

Serum hepatitis C levels and alanine transaminase (ALT) do not correlate with liver histopathology. [Abstract]. *Gastroenterology* 106:A866 (1994).

Ballardini G, Groff P, Pontisso P, et al.

Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A, B, C, and intercellular adhesion molecules. *J Clin Invest* 95:2967-2975, (1995).

Banderia A, Itohara S, Bonneville M, et al.

Extrathymic origin of intestinal intraepithelial lymphocytes bearing T-cell antigen receptor gamma delta. *Proc Natl Acad Sci USA*.88:43-47, (1991).

Baran MM,

A simultaneous assay for T- cells and B- cells using immune- beads. *Am J Clin Pathol* 83(2): 182 (1985).

Barnaba V, Franco A, Alberti A, et al.

Selective killing of hepatitis B envelope antigen-specific B cells by class

I-restricted, exogenous antigen-specific T lymphocytes. *Nature* 345:258-260(1990).

Basset SE, ThomasD, Brasky KM, et al.

Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. *J Virol* 73:1118-1126, (1999).

Battegay M, Fikes J, DiBisceglie AM, et al.

Patients with chronic hepatitis C have circulating cytotoxic T cells, which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. *J Virol* 69:2462-2470, (1995).

Bavnderia A, Itohara S, Bonneville M, et al.

Extrathymic origin of intestinal intraepithelial lymphocytes bearing T-cell antigen receptor gamma delta. *Proc. Natl. Acad. SCI USA* 88:43-47, (1991).

Bedassa P and Poynard ,

An algorithm for the grading of activity in chronic hepatitis C. The METAVER Cooperative study Group. *Hepatology*, 24:289-293,(1996).

Beld M, Penning M, van Putten M, et al.

Quantitative antibody responses to structural (core) and non-structural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood. *Hepatology* 29:1288-1298, (1996).

Bendelac A, Lantz O, Quimby ME, et al.

CD1 recognition by mouse NK1+ T lymphocyte. *Sciences* 268:863-865, (1995).

Benson R, Mayer RA, Zaruba M and Mckhann G.

Cellular auto fluorescence. Is it due to flavin? *J Histochem Cytochem* 27:44, (1979).

Bianchi L, and Gudat F,

Chronic hepatitis. In: MacSween RNM, AnthonyPP, Schruer P, Burt AD, Portmann BC (eds.): *Pathology of the liver*. 3rd ed. Edinburg, Churchill Livingstone, pp 348-395, (1994).

Bigos M, Baumgarth N, Jager GC, et al.

Nine color eleven-parameter immunophenotyping using three-laser flow cytometry. *Cytometry* 1,36(1): 36-45 (1999).

Biron CA,

Role of early cytokines, including alpha and beta interferons (INF-alpha/beta), in innate and adoptive immune responses to viral infections. *Semin Immuno* 10:383-390, (1998).

Bjorkander J, Cunningham-Rudles C, Lundin P, et al.

Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinaemia or IgG subclass deficiency. *American Journal of Medicine* 84:107-111 (1988).

Bonechhi R, Bianch G, Bordignon PP, et al.

Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1) and Th2. *J Exp. Med* 187: 129-134, (1998).

Borzio M, Bruno S, Roncalli M, et al.

Liver cell dysplasia is major risk factors for hepatocellular carcinoma in cirrhosis: a prospective study. *Gastroenterology* 108: 812-816, (1998).

Botarelli P, Brunetto MR, Minutello MA, et al.

T-lymphocytes response to hepatitis C virus in different clinical courses of the infection. *Gastroenterology* 104 y; 580-587(1993).

Brechot C,

Polymerase chain reaction. A new tool for the study of viral infection in hepatology. *J Hepatol* 11:124-129 (1994).

Brechot C,

Hepatitis C virus genetic variability: clinical implication. *J gastroentrol* 89:S41-S47, (1994).

Brillianti S, foli S, Gaiani S, et al.

Persistance of hepatitis C viremia without liver disease. *Lancet* 341:4649-4651, (1993).

Brown MC,

Control for flow cytometers in hematology and cellular immunology. *Ann Acad Sci* 468:93, (1989).

Bukh J, Miller R, and Prucell R, et al.

At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. *Proc. Natl. Acad. Sci USA* 90: 8238, (1993).

Bukh J, Prucell RH, Miller RH, et al.

Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes. *Semin. Liver Dis.* 15:41(1995).

Bukh J, Yangi M, Emerson SU, et al.

Course of infection and evolution of monoclonal hepatitis C virus strain H77 in chimpanzee transfected with RNA transcripts from an infectious cDNA clone. *Hepatology* 28: 319A, (1998).

Byrne JA, Oldstone MB.

Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: clearance of virus in vivo. *J Virol* 51:682-686(1984).

Camma C, Di Marco V, Lo Lacono O, et al.

Long term course of interferon -treated chronic hepatitis C. *Hepatology* 28:1121-1127,(1998).

Camma C, Guinta M, Chemello L, et al.

Chronic Hepatitis C: Interferon retreatment of relapsers. A meta analysis of individual patient data. *Hepatology* 30:801-807,(1999).

Carey JJ and Barry G.

Leukocytes antigens and monoclonal reagents: Production and characterization. In: Keren DF(ed). *Flow cytometer in clinical diagnosis*. Chicago. ASP.press Pp-41,(1994).

Cerny A, and Chisari FV.

Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence. *Hepatology* 30: 595-601, (1999).

Cha T-A, Beall E, Irvine B, et al.

At least five related, but distinct, hepatitis C viral genotypes exist. Proc. Natl. Acad. SCI USA 89:7144-7144, (1992).

Chadwik RG, Gallizzi J and Heathcote J.

Chronic persistent hepatitis: Hepatitis B virus markers and histological follow up. Gut 20:372-377, (1979).

Chang AM, Gruener NH, Southwood S, et al.

Identification of HLA-A3 and B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. J Immunol 162:1156-1164, (1999).

Chien D, Choo Q, Tabrizi A, et al.

Diagnosis of hepatitis C virus (HCV) infection by using immunodominant chimeric poly protein to capture antibodies. Reevaluation of the role of HCV in liver disease. Proc. Natl. Acad. SCI USA 89:10011-10015, (1992).

Choo Q, Kuo G, Ralston R, et al.

Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl. Acad. SCI USA 91:1294-1298, (1994).

Choo Q, Kuo G, Weiner A, et al.

Isolation of cDNA derived from a blood-born non-A, non-B viral hepatitis genome. Science 244:359, (1989).

Civeira MP, and Prieto J,

Early predictor of response to treatment in patients with chronic hepatitis C. J Hepatol 3: 237-243, (1999).

Cooksley WGE, Bradbear RA, Robinson W, et al.

The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis. Hepatology 6: 345-348, (1986).

Cooper S, Erikson AL, Adams EJ, et al.

Analysis of a successful immune response against hepatitis C virus. Immunity 10:439-449, (1999).

Cory-Cantilena, VanRaden M, Gible J, et al.

Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. *N Engl. J Med* 334: 1691-1696, (1996).

Crosland-taylor PG,

A device for counting small particles suspended in a fluid through a tube. *Nature* 171, 37-38(1953).

Cunningham RE,

Over view of flow cytometry and fluorescent probes for cytometry. *Methods Mol Biol.* 115:249-256 (1999).

Darwish NA, Abaas MO, Abdelfattah FM, et al.

Hepatitis C virus infection in blood donors in Egypt. *J.Egyptian Publ.Health Assos*, Vol.VII, No.3, 4:224-236, (1992).

Davis GL, Lau JYN,

Factors predictive of a beneficial response to therapy of hepatitis C. *Hepatology* 26: 122S-127S, (1997).

Davis GL, Lau JYN, Urdea MS, et al,

Quantitative detection of hepatitis C virus RNA with a solid phase signal amplification method: definition of optimal conditions for specimen collection and clinical application of interferon treated patients. *Hepatology* 19: 1337-1341 (1994).

Dean PN,

Data processing. In "Flow Cytometry and Sorting". Melamed MR., Lindmo T and Mendelsohn ML (eds.). Wiley-Liss, New York. Pp.415-444 (1991).

De Medina M and Schiff ER,

Hepatitis C: Diagnostic assays. *Semin Liver Dis* 15(1) :33-40,(1995).

Denis F, aussel L, Ranger S, Martin P, et al.

Prevalence of hepatitis C virus among patients with leprosy in several African countries and Yemen. *J.Med.Virology*, 43:14, (1994).

Desmet VG, Gerber M, Hoofnagle JH, et al.

Classification of chronic hepatitis: Diagnosis, grading and staging.

Hepatology 19: 1513-1520. (1994).

Dhumeaux D, Doeffoel M, Galmiche JP, et al.

A French consensus conference on hepatitis C: Screening and treatment. J Hepatol 27:941-944, (1997).

DiBisceglie AM,

Hepatitis C and hepatocellular carcinoma. Hepatology 26(suppl): 34s-38s, (1997).

Di Bisceglie AM,

Natural history of hepatitis C: Its impact in clinical management. Hepatology 31(4): 1014-1018, (2000).

DiBisceglie AM and Hoofnagle JH,

Therapy of chronic hepatitis C with alpha-interferon: the answer? Or more questions? Hepatology 13:601-603(1991).

Dienstag JL,

Non-A, non-B hepatitis. I. Recognition, epidemiology and clinical features. Gastroenterology 85: 439-462, (1983).

Diodati G, Bonneti P, Noventa F, et al,

Treatment of chronic hepatitis C with recombinant human interferon-2a: results of a randomized controlled clinical trial. Hepatology 19:1-5, (1994).

Dolganiuc A, Kodys K, Kopasz A, Marshall C, et al.

Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. J Immunol 1;170(11):5615-24 (2003).

Donahue J, Munoz A, Ness P, et al.

The declining risk of post-transfusion hepatitis C virus infection. N.Eng.J.Med.327: 369, (1992).

Durate EA, Novella IS, Weaver SC, et al.

RNA virus quasispecies: significance of viral disease and epidemiology. Infect Agents Dis. 3:201-214, (1994).

Dusheiko GM, and Rizzetto D,

The management of chronic hepatitis C. In: Dusheiko and Rizzetto (eds.); Synopsis in viral hepatitis: UK; Adelphi Communication ltd; pp: 1-20 (1992).

Eman RF,

Concomitant hepatitis virus infection in patients with *Schistosoma mansoni* .MD Thesis (Trop.Med.), Cairo University, (1994).

E-Ozylikan G, Tatar A, Hacibertasoglu B, et al.

Analysis of T-helper and T-suppressor lymphocytes subsets in patients with chronic hepatitis C infection. Hepatology, 28:436-437(1993).

Esteban J, Gomez J, Martel M, et al..

Transmission of hepatitis C by a cardiac surgeon. N.Engl.Med.334: 555, (1996).

Eyster ME, Diamondstone LS, Lien JM, et al.

Natural history of hepatitis C virus infection in multitransfused hemophiliac: Effect of coinfection with human immunodeficiency virus. The multicenter hemophilia cohort study. J Acquire Immune Def Synd. 6: 602-610, (1993).

Fang JWS, Albrecht JK, Jacobs S, et al.

Quantification of serum hepatitis C virus RNA. Hepatology 29:997-998, (1999).

Farci P, Alter HJ, Govindarajan S, et al.

Lack of immunity against reinfection with hepatitis C virus. Science 258:135-140, (1992).

Farci P, Alter HJ, Wong D, et al.

Prevention of hepatitis C virus infection in Chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci 91:7792, (1994).

Farci P, Alter HJ, Wong D, et al.

A long- term study of hepatitis C virus replication in non-A, non-B, hepatitis. N Eng J med 325:104, (1991).

Farci P, Shimoda A, Coiana A, et al.

The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. *Science* 288(5464):339-44, (2000).

Farci P, Shimoda A, Coiana A, et al.

The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. *Proc. Natl. Acad. Sci. U.S.A.* 93:15394-15399, (1996).

Fattovich G, Giustina G, Degos F, et al.

Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decomposition in cirrhosis type C. *J Hepatol* 27:201-205, (1997).

Ferarri C, Valli A, Galati L, et al.

T-cell response to the structural and non-structural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infection. *Hepatology* 19:286-295 (1994).

Flynn KJ, Belz GT, Altman JD, et al.

Virus specific CD8+ T cells in primary and secondary influenza pneumonia. *Immunity* 8: 683-691, (1998).

Fong TL, Shindo M, Feinstone SM, et al.

Detection of replicative intermediates of hepatitis C viral in liver and serum of patients with hepatitis C. *J Clin Invest* 88:1058-1060 (1991).

Forton DM, Wright M, Knapp S, Thursz MR, et al.

New insights into hepatitis c virus. *Clin Med*;2(6):554-9(2002).

Franco A, Guidotti Ig, Hobbs M, et al.

Pathogenic effector function of CD4+ T helper 1 cells in hepatitis B virus transgenic mice. *J Immunol* 159:2001-2008, (1997).

French Metaver Cooperative Study Group,

Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. *Hepatology* 20:15-20.(1994).

Gaweco AS, Van Thiel DH, Rustgi V, et al.:

Th1 cytokine pattern and defective IL-10 in chronic hepatitis C virus infected-liver. *Hepatology* 22:335A(1995).

Gerber MA, and Thung SN,

Cell lineage studies in human liver generation, proliferation and transformation. In: Sirica AE, Ed. The role of cell types in hepatocarcinogenesis. Boca Raton, FL: CRC Press, 209-226, (1992).

Gerlach JT, Dipolder HM, Jung MC, et al.

Recurrence of hepatitis C virus after loss of viral-specific CD4+ T cell response in acute hepatitis C. *Gastroenterology* 117:933-941, (1999).

Geulen O, Hansman M, Offergeld R, et al.

Maternal and fetal hepatitis C virus exposure by intrauterine transfusion. *Lancet*. 27:355 (9218): 1887-8, (2000).

Gillman JH, Geisinger KR, Richter JE, et al.

Primary hepatocellular carcinoma after chronic non-A, non-B post-transfusion hepatitis. *Ann Intern Med* 101:794, (1984).

Givan AL,

Principles of flow cytometry. An overview. *Methods in Cell Biology* 63:19-49, (2001).

Gonzalez-Peralta RP, Fang JWS, et al.

Immunopathology of chronic hepatitis C virus infection. *Hepatology* 20: 232A. (1994).

Gordon SC, Kodall VP, Silverman AL, et al.

Levels of hepatitis C virus DNA and liver histology in chronic type C Hepatitis. *Am J Gastroenterology* 89:1458-1461, (1994).

Grakoui A, Wychwski C, Lin C, et al.

Expression and identification of hepatitis C virus polyprotein cleavage products *Virology* 67:1385-1395, (1993).

Hata K, Ruzhang X, Iwatsuki S, et al:

Isolation, phenotyping, and functional analysis of lymphocytes from human liver. *Clin Immunology and Immunopathology*, 56:401-419(1990).

Hayashi J, Kawakami Y, Nabeshima A, et al.

Comparison of HCV RNA levels by branched DNA probe assay and by

competitive polymerase chain reaction to predict effectiveness of interferon treatment of patients with chronic hepatitis C virus. *Dig Dis Sci* 43:384-391, (1998).

He XS, Rehermann B, Lopez-Labrador FX, et al.

Quantitative analysis of hepatitis C virus-specific CD8⁺ T cells in peripheral blood and liver using peptide-MHC tetramers. *Proc. Natl. Acad. Sci. USA* 96: 5692-5697, (1999).

Heathcot J,

Antiviral therapy for patients with chronic hepatitis C. *Semin Liv Dis* 20(2):185-199, (2000).

Hennig H, Kirchner H, Kluter H, et al.

Failure of third generation immunoblot assay to detect hepatitis C virus core antibodies. *Transfusion* 39:335-6, (1999).

Hiramatsu N, Hayashi N, Haruna Y, et al.

Expression of HCV related antigen and liver damage in patients with chronic hepatitis C. *Hepatology* 16:544, (1992).

Hiramatsu N, Hayashi N, Katayama K, et al.

Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. *Hepatology* 19: 1345-1359, (1994).

Hiroishi K, Kita H, Kojima M, et al.

Cytotoxic T lymphocytes response and viral load in hepatitis C viral infection. *Hepatology* 25:705-712, (1997).

Hoffman RM, Diepolder HM, Zachoval R, et al.

Mapping of immunodominant CD4⁺ T lymphocytes epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. *Hepatology* 21:632-638(1995).

Hofgartner WT, Kant JA, Weck KE, et al.

Hepatitis C virus quantitation: optimization of strategies for detecting low-level viremia. *J Clin Microbiol* 38:888-891, (2000).

Honda M, Brown EA, Lemon SM, et al.

Stability of stem-loop involving the initiator AUG controls the efficiency of internal initiation of translation on hepatitis C virus RNA. RNA. J Immunol 2:955-968, (1996).

Hopf U, Moller B, Kuther D, et al.

Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol 10:76, (1990).

Huang L, Sye K, Crispe IN, et al.

Proliferation and apoptosis of B220+ CD4-CD8-TCR alpha beta intermediate T cells in the liver of normal adult mice: Implication for 1pr pathogenesis. Int. Immunol 6:553-540, (1994).

Hughton M, Weiner A, Han J, et al.

Molecular Biology of the hepatitis C virus: implication for diagnosis, development and control of viral disease. Hepatology 14:381(1991).

Hytioglou E, thung S Michael A, et al.

Histological classification and quantitation of the severity of chronic hepatitis: keep simple. Semin Liver Dis 15(4): 414-421, (1995).

International Group,

Acute and chronic hepatitis revisited. Lancet 2:914-919(1977).

International working party,

Terminology of nodular hepatocellular lesions. Hepatology 22: 983-993, (1995).

Ishak k, Baptista A, Brianchi L, et al.

Histological grading and staging of chronic hepatitis. J Hepatol 22:696-699, (1995).

Ishikawa R and Biron C,

IFN induction and associated changes in splenic leukocyte distribution Immunol 150:3713-3727(1993).

Jeffers IJ, Cheinquer H, Hunt W, et al:

Correlation of ALT level and severity of hepatitis histology with a new

quantitative HCV-RNA method in patients with chronic hepatitis C. *Hepatology*, 16:551,(1992).

Jin Y, Shih JWK, Berkower I:

Human T cell response to the surface antigen of hepatitis B virus. Endogenous and exogenous antigen. *J Exp Med* 168:293-306(1988).

Johnson R, Gretch G, Yamabe H, et al.

Membranoproliferative glomerulonephritis associated with chronic hepatitis C infection. *N. J. Med.* 428:465, (1993).

Kachel VC,

Flow cytometric instrumentation for scientific and clinical use. *Ann NY Acad Sci* 468:28,(1986).

Kamel M, Abdel-Ghafar Y, Wassif MA, et al.

High HCV prevalence in Egyptian blood donors. *Lancet*, 15:340(8816): 427, (1992).

Kamel M, Miller FD, El-Masry AG, et al.

The epidemiology of schistosomiasis, hepatitis B and hepatitis C infection in Egypt. *Ann.Trop.Med.Parasitol.*88 (5): 501-9, (1994).

Kasahara A, Hayashi Nk, Mochizuki K, et al.

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. *Hepatology* 27:1394-1402, (1998).

Kashii Y, Shimuzi Y, Nambu S, et al.

Analysis of T cell receptor V beta repertoire in liver infiltrating lymphocytes in chronic hepatitis C. *J Hepatol* 26: 462-470, (1997).

Kassem AS, el-Nawawy AA, Maassoud MN, SY, et al.

Prevalence of hepatitis C virus infection and its vertical transmission in Egyptian pregnant women and their newborns. *J Trop Pediatr.*46 (4): 231-3, (2000).

Kelen GD, Green GB Prucell RH, et al.

Hepatitis B and hepatitis C in emergency department patients. *N.Eng.J.Med.* 320(21): 1399-1404, (1992).

Kenny-Walsh E,

Clinical outcomes after hepatitis infection from contaminated antiglobulin. *N Engl. J Med* 340: 1228-1233, (1999).

Killenbergs PG,

Extrahepatic manifestation of chronic hepatitis C. Seminar in Gastrointestinal Disease Vol 11. No 2(April), pp 62-68, (2000).

Kinkhabwala M, Sehajpal P, Skolnik E, et al.

A novel addition to the T cell repertoire: Cell surface expression of tumor necrosis factor/cachectin by activated normal human T cells. *J Exp Med* 171: 941-946, (1990).

Kiosawa K, Sodeyama T, Tanaka E, et al.

Inter relationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. *Hepatology* 12: 671-675, (1990).

Knodel RG, Ishak H, Black WC, et al.

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. *Hepatology* 1:431-435, (1981).

Kobayashi M, Chayama K, Arase Y, et al.

Predictive value of different hepatitis C serological assays in the treatment of chronic hepatitis C with interferon alpha. *J Gastroenterol* 34: 94-99, (1999).

Kobayashi M, Kumada H, Arase Y, et al.

Usefulness of hepatitis C virus RNA counts by second-generation b-DNA-probe in chronic hepatitis C based on type HCV genotype. *J Gastroenterol* 33:223-8, (1998).

Koff RS,

Hepatitis vaccines. *Infect Dis Clin North Am* 15(1):83-95. Review(2001).

Koff RS,

Risk associated with hepatitis A and hepatitis B in patients with hepatitis C. *J Clin Gastroenterol* 33(1):20-26, (2000).

Koretz RL, Overby LR and Gitnick GL.

The long term course of non-A, non-B, post-transfusion hepatitis. *Gastroenterology*, 79:893-898, (1980).

Koretz RL, Abby H, Coleman E, et al.

Non-A, non-B post-transfusion hepatitis. Looking back in second decade. *Ann. Intern Med.* 119:120, (1993).

Koss LG, Czerniac KB, Herz F, et al.

Flow cytometric measurements of DNA and other cell compartments in human tumors: a critical appraisal. *Hum Pathol*; 20(6):528-48.(1989).

Kozeil MJ, Dudley D, Afdhal N, et al.

HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis c virus: Identification of multiple epitopes and characterization of patterns of cytokines release. *J Clinical invest* 96:2311-2321(1995).

Kuhns M, de Medina M, MacNamara A, et al.

Detection of hepatitis C virus in hemodialysis patients. *J Am Soc Nephrol* 4:1491-1497, (1994).

Kuo G, Choo QL, Alter A, et al.

An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. *Science* 344:362, (1989).

Lai ME, Mazzoleni AP, Argioli f, et al.

Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassemic children. *Lancet* 343:388-390 (1994).

Lamonaca V, Missale G, Urbani S, et al.

Conserved hepatitis C virus sequences are highly immunogenic for CD4+ T cells. Implication for vaccine development. *Hepatology* 30:1088-1089, (1999).

Landay L, George SK, Bray RA, et al.

Phenotyping of cells of the immune system: methods application. In: Coon JS and Weinstein RS(eds):Diagnostic flow cytometry. Williams and Wilkins. London Pp-59 (1991).

Landay L and Muirhead KA.

Procedural guidelines for performing immunophenotyping by flow cytometry. Clin Immunol Immunopathol 52:48(1989).

Lanier LL,

NK cell receptors. Ann Rev Immunol 16:359-393, (1998).

Laskus T, Radkowski M, Wang LF, et al.

Search for hepatitis C virus extra hepatic replication sites in patient with acquired immunodeficiency syndrome: Specific detection of negative - strand viral RNA in various tissues. Hepatology, 28:1398-1401, (1998).

Lau D, Kleiner DE, GhanyMG, et al.

10 year follow up after interferon alfa therapy for chronic hepatitis C. Hepatology 28:1121-1127,(1998).

Lau Gk, Lesniewski R, Hohnson RG, et al.

Immunoglobulin M and A in chronic hepatitis C virus infection. Journal of Medical virology44: 1-4(1994).

Leavy S, Todd S, Maecker H, et al.

A molecule involved in signal transduction and cell adhesion in the immune system. Annul Rev Immunol 16:89-109, (1998).

Lechmann M, Ihlenfeldt HG, Braunschweiger I, et al.

T and B cell responses to different hepatitis C virus antigen in patients with chronic hepatitis C infection and healthy anti-hepatitis C virus positive blood donors without viremia. Hepatology 24:790-795(1996).

Lefkowitz JH, Schiff ER Davis GL et al.

Pathological diagnosis of chronic hepatitis c. Gastroenterology 104:595-603, (1993).

Leroux-Roels G, Esquivel CA, Deleys R, et al.
Lymphoproliferative responses to hepatitis C virus core, E1, E2, and

NS3 in patients with chronic hepatitis C infection treated with interferon alfa. *Hepatology* 23:8-16(1996).

Lewis DE,

Cytochemistry & cell surface immunofluorescence. Baur KD, Duquer RE and Shankey TV(eds): *Clinical flow cytometry*. Maryland, USA. Pp-147 (1993).

Li XM, Reddy KR, Jeffers LJ, et al.

Indeterminate hepatitis C. *Lancet* 341:835, (1993).

Liaw YF, Lee CS, Tsai SL, et al.

T cell mediated hepatocytotoxicity in patients with hepatitis C virus infection. *Hepatology* 22:1368-1373, (1995).

Lindsay KI,

Therapy of hepatitis C. Overview. *Hepatology*, 26(3),Suppl. 1:71s-77s, (1997).

Lohman BL, Razvi ES, Welsh RM, et al.

T-lymphocytes down-regulation after acute viral infection is not dependent on CD95 (Fas) receptor -ligand interaction. *J Virol* 70: 8199-8203, (1996).

Lu RH, Hwang SJ, Chan CY, et al

Measurements of serum HCV RNA in patients with chronic hepatitis C: Comparison between Amplicor HCV Monitor system and branched DNA signal amplification assay. *J Clin Lab Anal* 12:121-125, (1998).

Ludwig J,

The nomenclature of chronic active hepatitis: an obituary. *Gastroenterology* 105:274-278,(1993).

Lynch S, Kelleher D, Mc Manus R, et al.

RAG1 And RAG2 expression in human intestinal epithelium: Evidence of extrathymic T cell differentiation. *Eur J Immunol* 25:1143-1147,(1995).

MacCarthy RC and Fetterhoff TJ.

Issues for quality assurance in clinical flow cytometry. *Arch Pathol Lab Med* 113:658 (1989).

Mac Coy JP and Lovett EJ,

Basic principle in clinical flow cytometry. In: Keren DF(ed): Flow cytometry in clinical diagnosis. Chicago. ASCP. Pp-19 (1989).

MacDonald HR,

NK cells and T-cell receptor-alpha/beta+ cells: New clues to their origin, specificity, and function. J Exp. Med 182:633-638, (1995).

MacDonald AJ, Duffy M, Brady MT, J, et al.

CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons. J Infect Dis 15;185(6):720-7(2002).

MacHutchison JG, Gorden SC, Schiff ER, et al.

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl. J Med 339: 1485-1492, (1998).

Mac Miking J, Xie QW and Nathan C, et al.

Nitric oxide and microphage function. Ann Rev Immunol 15:323-350, (1997).

MacPhee PJ, Schmidit E, Groom AC, et al.

Intermittence of blood flow in liver sinusoids, studied by high- resolution in vivo microscopy. Am J Physiol 269: G692-G698, (1995).

Major M, Mihalik K, and Fernandez J, et al.

Long term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. J Virol 73:3317-3325, (1999).

Marrogi AJ, Cheles MK, Gerber MA, et al.

Chronic hepatitis C. Analysis of host immune response by immunohistochemistry. Arch Pathol Lab Med 119: 232-237, (1995).

Martell M, Esteban JI, Quer J, et al.

Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasispecies nature of HCV genome distribution. J Virol 66:3225-3229, (1992).

Martell M, Esteban J, Quer J, et al.

Dynamic behavior of hepatitis C virus quasispecies in patients undergoing orthotopic liver transplantation. *J Virol* 68:3425-3436, (1994).

Marti GE,

Normal human blood density gradient lymphocytes subset analysis: An interlaboratory flow cytometric comparison of 85 normal adults. *Am J Hematol* 20 (1): 41, (1985).

Martin P, Fabrizi F, Dixit V, et al,

Automated RIBA hepatitis C virus strip immunoblot assay for reproducible HCV diagnosis. *J Clin Microbiol* 36:187-190, (1998).

Martinot-Peignoux M, Boyer N, Le Breton V, et al.

A new step toward standardization of serum hepatitis C virus quantification in patients with chronic hepatitis C. *Hepatology* 3: 726-729, (2000).

Mathurin P, Moussalli J, Cadranel JF, et al.

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. *343: 388-390* (1994).

McQuillan GM, Alter MJ, Mayor LA, et al.

A population based serological studies of hepatitis C virus infection in United States. Paper presented in viral hepatitis and Liver Disease. Edizioni Minerva Medica, (1997).

Mehal WZ, Juedes AE, Crispe IN, et al.

Selective retention of activated T cells by the normal liver. *J Immunol* 163: 3202-3210, (1999).

Mercier B, Burlot L, Ferec C, et al.

Simultaneous screening of HBV RNA and HCV RNA genomes in blood donation using a novel TaqMan PCR assay. *J Virol Methods* 77:1-9, (1999).

Michiko T, Gotaro Y, Rieko M, et al.

Natural course of chronic hepatitis C. *Am J Gastroenterology*, 88(2):240-243, (1993).

Minutello MA, Pileri P, Unutmaz D, et al.

Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. *J Exp Med* 178:17-25(1993).

Misiani R, Bellavita P, Fenili D, et al.

Interferon-alpha-2a therapy in cryoglobulinemia associated with hepatitis C virus. *N. Engl. J. Med.* 330: 751, (1994).

Mita E, Hayashi N, Iio S, et al.

Role of Fas ligand in apoptosis induced by hepatitis C virus infection. *Biochem Res Commun* 204: 468-474, (1994).

Mitsui T, Iwano K, Masuko K, et al.

Hepatitis C virus infection in medical personnel after needle stick accident. *Hepatology* 166:1109, (1992).

Modlin J,

Poliovirus. In: Mandell GL, Dolin R, (eds.). *Principle and Practice of Infectious Diseases*. Vol. 2. Philadelphia: Churchill Livingstone, pp 1895-1903 (2000).

Mohammed MK, Hussein MLT, Massoud AA, et al.

Study of the risk factors of viral hepatitis C infection among Egyptians applying for work abroad. *J Egypt Public health Assoc.* 71: 78-111(1996).

Mokaida N, Hishinuma A, Zachariae A, et al.

Regulation of human Interleukin 8 gene expression and binding of several other members of intercrine family to receptors of interleukin 8. *Adv Exp Med Biol* 305:31-38, (1991).

Morisson LA, Lukacher A, Braciale VL, et al.

Differences in antigen presentation to HLA class I and class II-restricted Influenza virus specific cytolytic T lymphocytes clones. *J Exp Med* 163:903-921 (1986).

Moriyama T, Guilhot S, Klopchin K, et al.

Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus in transgenic mice. *Science* 248:361-364(1990).

Mossman TR, Cherwinski H, Bond MW, et al.

Tow types of murine helper T cell clone. I. Definition according to profile of lymphokine activities and secreted proteins. *J Immunol* 136:1348-1357, (1986).

Mukadia N, Hishinuma A, Zachariae CO, et al.

Regulation of human interleukin 8 gene expression and binding of different other members of the intercrine family to receptors of interleukin-8. *Adv Exp. Med Biol.* 305: 31-38, (1991).

Murai M, Yoneyama H, Harada A, et al.

Active participation of CCR5 (+) CD8 (+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. *J clin Invest* 104: 49-57, (1999).

Murali-Krishna K, Altman JD, Surest M, et al.

Counting antigen -specific CD8 T cells: A reevaluation of bystander activation during viral infection . *Immunity* 8:177-187, (1998).

Nagayoma R, Miyake AK, Tsuda F, et al.

Ig M antibody to a hepatitis C virus core peptide (CP14) for monitoring activity of liver disease in patients with acute and chronic hepatitis C. *Journal of medical virology* 42:311-317(1994).

Nakamoto Y, Guidotti LG, Kuhlen CV, et al.

Immune pathogenesis of hepatocellular carcinoma. *J Exp Med* 188: 341-350, (1998).

Napoli J, Bishop A, McGuinness P, et al.

Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1 associated cytokines. *Hepatology* 24:759,(1996).

Narah AT and Teressa LW,

Viral hepatitis A through G. In: *Gastrointestinal and liver Disease.* Sleisenger M and Feldman M.(eds.). W.B Saunders. Chapter 68 p1144-1165.(1998).

National institute of health consensus development conference,

Panel statement. Management of hepatitis C. Hepatology. 26 (suppl 1):25-105(1997).

Negro F, Pacchioni D, Shimizu Y, et al.

Detection of intrahepatic replication of hepatitis C virus RNA by in-situ hybridization and comparison with histopathology. Proc. Natl. Acad. Sci USA, 89:2247-2251, (1992).

Nelson&Lau 1998

Nelson DR, Marousis CG, Davis GL, et al.

The role of hepatitis C virus cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 158: 1473-1481, (1997).

Nemichinov LG,

Development of plant derived subunit vaccine candidate against hepatitis C virus. Arch Virol. 145(12):2557-73, (2000).

Niederau C, Lang S, Heintges T, et al.

Prognosis of chronic hepatitis C: Results of a large prospective cohort study. Hepatology 28;1687-1695, (1998).

Nooman ZM, El-Gohary A, Hassan AH, et al.

Autoantibodies to HCV in blood donors in Suez-Egypt (Abstract). Society of Hepatology 9th annual meeting, April 24-26, Cairo (1991).

Numann A, Lam N, Dahari H, et al.

Hepatitis C virus dynamic and the antiviral efficacy of interferon – alpha therapy. Science 282:103-107, (1998).

Nuti S, Rosa D, Vaiani NM, et al.

Dynamic of intrahepatic lymphocytes in chronic hepatitis C: enrichment for valpha-24+ T cells and rapid elimination of effector cells by apoptosis. Eur J Immunol 28: 3448-3455, (1998).

Ochsenbein A, Fehr T, Lutz C, et al.

Control of early viral and bacterial distribution and disease by natural antibodies. *Science* 286:2156-2159, (1999).

O'Farrelly C and Crispe IN,

Prometheus through the looking glass: Reflections on the hepatic immune system. *Immunol Today* 20:394-498, (1999).

Ogata N, Alter HJ, Miller HR, et al.

Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. *Proc. Natl. Acad. Sci. USA* 88:3392-3396, (1991).

Ohto H, Terazawa S, Sasaki N, et al.

Transmission of hepatitis C virus from mother to infants. *N. Engl. Med.* 330: 744, (1994).

Okamoto H, Kojima M, Okada s, et al.

Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. *Virology* 190:894-899, (1992).

Okuda M, Hino K, Korenaga M, et al.

Difference in hypervariable region 1 quasispecies of hepatitis C virus in human serum, peripheral mononuclear cells and liver. *Hepatology* 29:217-222, (1999).

Onji M, Kikuchi T, Kumon I, et al.

Intrahepatic lymphocytes subpopulations and HLA class I antigen expression by hepatocytes in chronic hepatitis C. *Hepatogastroenterology* 39: 340-344, (1992).

Pantaleo G, Demarest GF, Schaker T, et al.

The quantitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. *Proc. Natl. Acad. Sci. USA* 94:254-258, (1997).

Pawlotsky JM,

Measuring hepatitis C viremia in clinical samples: Can we trust the assays? *Hepatology* 26:1-4, (1997).

Perrillo RP:

The role of liver biopsy in hepatitis C. *Hepatology*, 26:57s-61s, (1997).

Pernollet M, Jouvin-Marche E, Leroy V, et al.
Simultaneous evaluation of lymphocyte subpopulations in the liver and in peripheral blood mononuclear cells of HCV-infected patients: relationship with histological lesions. *Clin Exp Immunol* 130 (3):518-25(2002).

Pessoa MG and Wright TL,
Hepatitis C infection in transplantation. *Clin Liver Dis* 1: 663-690, (1997).

Peters D, Branscomb, E, Dean P, et al.
The LLNL high-speed sorter: Design features, operational characteristics, and biological utility. *Cytometry* 6, 290-301(1985).

Pham B-N, Mosnier JF, Walker F, et al:
Flow cytometry CD4+/CD8+ ratio of liver derived lymphocytes correlate with viral replication in chronic hepatitis B. *Clin Exp Immunol* 97:403-410(1994).

Pileri P, Umatsu Y, Campagnli S, et al.
Binding of hepatitis C to CD81. *Science* 282:941, (1998).

Pinkel D, and Stovel R,
Flow chambers and sample handling. In "Flow Cyrtometry: Instrumentation and Data Analysis". Van Dilla MA, Dean PN, Laerum OD, and Melamed MR. (eds.). Academic Press, London, pp.3-128 (1985).

Pontisso P, Ruvoletto MG, Fattovich G, et al.
Clinical and virological profiles in patients within multiple hepatitis C virus infection. *Gastroenterology* 105: 1529, (1994).

Popper H, Dienstag JL, Feinstone SM, et al.
The pathology of viral hepatitis in chimpanzees. *Arch A Pathol Anat Histo* 1387:91-106 (1980).

Poynard T, Bedossa P, and Opolon P,
Natural history of liver fibrosis progression in patients with hepatitis C. *Lancet* 349: 825-832, (1997).

Poynard T, MacHutchison J, Goodman Z, et al.

Is "a la carte" combination interferon- alpha-2b plus Ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? *Hepatology* 31:213-218, (2000).

Poynard T, Marcelline P, Lee S, et al.

Randomized trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. *Lancet* 352:1426-1432, (1998).

Prince AM, Brotman B, Inchauspe G, et al.

Pattern and prevalence of hepatitis C virus infection in post-transfusion NANB hepatitis. *Journal of infectious disease*. 167:1296-1301, (1993).

Raff MC,

Role of thymus-derived lymphocytes in the secondary humoral immune response in mice. *Nature* 226:1257-1259(1970).

Rall C, and Dienstag J,

Epidemiology of hepatitis C infection. *Semin. Of Gastrointest.Dis.*6: 3, (1995).

Ray SC, WangY, Laeyendecker O, et al.

Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: Hypervariable region 1 as a decoy. *J Virol* 73:2938-2946, (1999).

Rehermann B,

Interaction between the hepatitis C virus and the immune system. *Seminar in liver Disease* 20(2):127-141, (2000).

Rehermann B, Chang KM, McHutchison J, et al.

Differential T lymphocytes responsiveness to the hepatitis C and B viruses in chronically infected patients. *J Virol* 70: 7092-7102, (1996).

Rehermann B, Chang KM, MacHatchinson JG, et al.

Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response, disease activity and viral load in patients with chronic hepatitis C virus infection. *J Clin Invest* 98:1430-1440, (1996).

Rehermann B and Chsari FV,

Cell mediated immune response to the hepatitis C virus. *Curr Top Microbiol Immunol* 242: 299-325, (2000).

Rehermann B, and Manns MP,

Immunological aspects of hepatitis B&C. Current options in gastroenterology, 12:554-558(1996).

Reichard O, Norkrans G, Fryden A, et al.

Comparison of 3 quantitative HCV RNA assays-accuracy of base line viral load to predict treatment outcome in chronic hepatitis C. *Scand J Infect Dis* 30: 441-446, (1998).

Reiser M, Marousis CG, Nelson DR, et al.

Serum interleukin 4 and 10 levels in patients with chronic hepatitis C virus infection. *Journal of Hepatology* 26:471k-478(1997).

Renzi P and Ginns LC,

Analysis of T-cell subsets in normal adults. Comparison of whole blood lysis technique of ficoll-hypaque separation by flow cytometry. *J Immunol Mryhofd* 98:53 (1987).

Ridge JP, Di Rosa F, Matzinger P, et al.

A conditioned dendritic cell can be a bridge between a CD4+ T-helper and a T killer cell. *Nature* 393:474-478, (1998).

Rodriguez-Lopez M, Rieza-boj JI, Ruiz M, et al.

Immunogenicity of hepatitis C virus proteins: selection and modification of peptide epitopes to assess hepatitis C virus genotypes by ELISA. *J Gen Virol* 80:727-738, (1999).

Roederer M, De Rosa S, Gerstein R, et al.

8 Colour, 10- parameters flow cytometry to elucidate complex leukocyte heterogeneity. *Cytometry* 1; 29(4): 328-339, (1997).

Rosa D, Campagnoli S, Moretto C, et al.

A quantitative test to estimate hepatitis C virus: Cytofluorometric Acad. *SCI USA* 93:1759-1763, (1996).

Saeed AA, El-Admawy AM, EL-Rasheed A, et al.

HCV infection in Egyptian volunteer blood donors in Riyadh. *Lancet*, 17:338(8764): 459-460, (1991).

Salama H, Esmat C, Medhat E, et al.

The frequency of anti-HCV among Egyptian rural school children: Its relation to schistosomiasis. *Sci.Med.J.Cairo, Med. Synd.* 7(2): 117-126, (1995).

Salazar-Mather TP, Ishikawa R, and Biron CA,

NK cell trafficking and cytokine expression in splenic compartments after IFN induction and viral infection *Immunol* 157:3054-3064, (1996).

Saldanha j, Lelie N and Heathe A,

Standardization, quantification and quality control of assays of HCV-RNA. *Viral Hepatol Rev* 5: 1-11, (1991).

Sallusto F, Lenig D, Mackay CR, et al.

Flexible program of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. *J Exp Med* 187: 875-883, (1998).

Scheuer PJ,

Classification of chronic viral hepatitis: a need for reassessment. *J Hepatol* 13: 372-374, (1991).

Schiff E,

The role of hepatitis C virus in liver disease. *J Gastroenterol Hepatol*, (suppl.1):29-30,(1991).

Schillit HJ, Achafers S, Deiwick A, et al.

Extramedullary erythropoiesis in human liver grafts. *Hepatology* 21:689-696, (1995).

Schmidt WS, Wu P, Brashear D, et al.

Effect of Interferon therapy on hepatitis C virus RNA in whole blood, plasma and peripheral mononuclear cells. *Hepatology* 28:1110 - 1116,(1998).

Schupper H, Hayashi P, Scheffel J, et al.

Peripheral blood mononuclear cell responses to recombinant Hepatitis C

virus antigens in patient with chronic hepatitis C. *Hepatology* 18:1055-1060(1993).

Scognamiglio P, Accapizato D, Casciani A, et al.

Presence of effectors CD8+ T cells in hepatitis C virus-exposed healthy sero-negative donors. *J Immunol* 162:6681-6689, (1999).

Seamer LC, Bagwell CB, Barden L, et al.

Proposed new data file standard for flow cytometry, version FCS 3.0. *Cytometry* 28:118-122(1997).

Seeff LB,

Hepatitis C from a needle stick injury. *Ann Intern Med* 115:P411 (1991).

Seeff LB, Hollinger FB, Alter HJ, et al.

Long- term morbidity of transfusion- associated hepatitis (TAH) C. *Hepatology* 28: 407A, (1998).

Seeff LB, Miller RN, Rabkin CS, et al.

45-Year follow-up of hepatitis C virus infection in healthy young adults. *Ann Intern Med* 132: 105-111, (2000).

Seef L, Zimmerman H, Wright E, et al.

A randomized double- blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis. A veteran's administration cooperative study. *Gastroenterology* 72:111. (1977).

Selby MJ, Choo QI, Verger K, et al.

Expression, identification and sub cellular localization of the proteins encoded by the hepatitis C virus genome. *Journal of General Virology* 74:1103-1113(1993).

Shakil A, Conry-Contella, Alter HJ, et al.

Volunteer blood donors with antibodies to hepatitis C virus: Clinical, biochemical-and histologic features. *Ann Intern Med* 123: 330-337, (1995).

Shapiro HM,

Technical development in FMC. *Hum Pathol.* 17(7): 649 (1986).

Shapiro HM,

Laser beam shaping and spot size. In "Current Protocols in Cytometry". Robinson JP (ed.). Jwiley, New York, pp.161-165 (1997).

Sheih YSC, Shim KS, Lampertico P, et al.

Detection of hepatitis C virus sequences in liver tissue by the polymerase chain reaction. Lab Invest 65:408-411, (1991).

Sherlock S and Dooley J,

Chronic Hepatitis. In: Diseases of the liver and biliary system (10th edition); Sherlock S, and Dooley J (eds.); Blackwell Scientific Publications, USA, pp: 324-533, (1997).

Shiari M, Okada H, Nishiooka M, et al.

An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virology. 68:3334-3342, (1994).

Shibata M, Morizane T, Uchida T, et al.

Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis C virus infection. Lancet 351: 1773-1777, (1998).

Shields PL, Morland CM, Salmon M, et al.

Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment within hepatitis C infected liver. J Immunol 163: 6236-6243, (1999).

Shiffman ML, Hofmann CM, Contos MJ, et al.

A randomized, controlled trial of maintenance interferon therapy for patients with hepatitis C virus and persistent viremia. Gastroenterology 117:1164-1172, (1999).

Shimizu Y, Igarashi H, Kiohara T, et al.

A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology 223:409-412, (1996)

Shimizu YK, Yoshikuta H, Hijikata M, et al.

Neutralizing antibodies against hepatitis C virus and the emergence of

neutralization escape mutants. *J Virol* 68:1494-1500, (1994).

Sigal LJ, Crotty S, Andino R, et al.

Cytotoxic T-cell immunity to virus-infected non- haemopoietic cells requires presentation of exogenous antigen. *Nature* 298:77-80, (1999).

Simmonds P, Alberti A, Alter HG, et al.

A proposed system of the nomenclature of hepatitis C viral genotypes. *Hepatology* 19:1321-1324, (1994).

Simmonds P, Rose K, Graham S, et al.

Mapping of phenotype specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type specific peptides to serologically differentiate infections with HCV types 1,2 and 3. *J Clin Microbiol* 31:1493-1503 (1993).

Simmonds P, Zhang LQ, Watson HG, et al.

Hepatitis C quantification and sequencing in blood products, hemophiliacs and drug users. *Lancet* 336:1469-1472, (1990).

Soni PN, Khakoo SI and Dusheiko GM,

Viral hepatitis In: *Recent Advances in Gastroenterology*. Pounder R(ed.).Churchil Livingstone,London, Pp 235-266, (1994).

Steven CE, Taylor PE, Pindych J, et al.

Epidemiology of hepatitis C virus. A preliminary study in volunteer blood donors. *JAMA*, 263(1) 49-53, (1990).

Sugimoto K, Stadanlick J, Ikeda F, et al.

Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. *Hepatology* ;37(3):590(2003).

Taboune M, Galatola G, Secreto P, et al.

Serum level of anti-hepatitis C virus IgM core antibodies may predict the course of interferon-alpha therapy in chronic hepatitis C. *J Viral Hepatol* 1:155-157 (1994).

Taboune M, Secreto P, Marini C, et al.

Pre-treatment levels of anti-HCV core IgM antibodies are closely associated with response to alpha interferon therapy in chronic hepatitis C patients. *J Gastroenterol Hepatol* 9: 287-291, (1997).

Takada N, Takase S, Emoto N, et al.

Difference in hepatitis C virus genotypes in different countries. *J Hepatol* 17:277-283, (1993).

Takahashi M, Yamada G, Miyamoto R, et al.

Natural courses of hepatitis C. *The American Journal of Gastroenterology*, 88(2):240-243, (1993).

Takamizawa A, Mori C, Fuke I, et al.

Structure and organization of hepatitis C virus genome isolated from human carriers. *J Virol* 65:1105-1113, (1991).

Takeuchi T, Katsume A, Tanaka T, et al.

Real time detection system for quantification of hepatitis C virus genome. *Gastroenterology* 116:636-642, (1999).

Terrault NA and Wright TL,

Viral hepatitis A through G: In: Sleisenger and Feldman (eds.). *Gastroenterology and Liver Disease*. WB. Saunders Company. Pp: 1144, (1998).

Thaler MM, Crowford K, Kansopon J, et al.

Selective transmission of HCV variants from mothers to infants. *Hepatology* 18:106A, (1993). Abstract.

Tong MJ, Blatt LM, MC Hutchison JG, Co RL, et al.

Prediction of response during interferon alpha-2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. *Hepatology* 26:1640-5, (1997).

Trabaud MA, Bailly F, Si-Ahmed SN, et al.

Comparison of the first international standard of nucleic acid amplification technology (NAT) assays for HCV RNA. WHO collaborative study group. *Vox Sang* 76: 149-158, (1999).

Tragnose F,

Flow cytometry, principles and applications. *Cancer Invest* 2 (2): 239 (1984).

Van der Poel CL,

Hepatitis C virus infection from blood and blood products. *FEMS Microbiol Rev* 14:241-246, (1994).

Van der Poel CL, Cuypers HT, Reesink HW, et al.

Hepatitis C virus six years on. *Lancet* 341:1475-1479, (1994).

Van Doorn L,

Review: molecular biology of the hepatitis C virus. *J Med Virol* 43:345-356, (1994).

Van Doorn L, Quint W, Tsiquaye K, et al.

Longitudinal analysis of hepatitis C virus infection and genetic drift of the hyper variable region. *J Infect Dis.* 169:1226-1235, (1994).

Vaquer P, Canet R, Liompart A, et al.

Histological evaluation of chronic hepatitis C. Factors related to progression. *Liver* 14:265-269, (1994).

Vassalli P.

The pathophysiology of tumor necrosis factors. *Annu Rev Immunol* 10; 411-452, (1992).

Vilcek JSG.

Interferon and other cytokines. IN: Fields BN, Howley PM, (eds.). *Fundamental Virology*. Vol. 11. Philadelphia: Lippincott-Raven, pp341-365, (1996).

Vogt M, Lang T, Frosner G, et al.

Prevalence and outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation blood donor screening. *N Engl. J Med* 341: 866-870, (1999).

Von Boehmer H.

The developmental biology of T lymphocytes. *Annu Rev Immunol* 6:309-326, (1988).

Wagner L, Yang OO, Garcia-Zepeda EA, et al.

Beta chemokines are released from HIV-1-specific T-cell granules complexed to proteoglycans. *Nature* 391: 908-911, (1998).

Wang C, Sun J, Wang L, et al.

Combined liver and pancreas transplantation induces pancreas allograft tolerance. *Transplant Proc.* 29:1145-1146, (1997).

Wassim H, Shaker W, sherif A, et al.

Prevalence of HCV in Egypt. *Hepatology*, 25(1): 167-171, (1996).

Watson JV.

The early fluidics and optical physics of cytometry. Review. *Cytometry* 15;38(1):2-14,(1999).

Weiner AJ, Brauer MJ, Rosenblatt J, et al.

Variable and hypervariable domains are found in the region of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. *Virology* 180:842-848, (1991).

Weiner A, Erickson Al, Kansopon J, et al.

Persistent hepatitis C virus infection in chimpanzee is associated with emergence of a cytotoxic T lymphocytes escape variant. *Proc. Natl. Acad. SCI. USA.* 92: 2755-2759, (1995).

Weiner AJ, Thaler M, Crawford K, et al.

A unique, predominant hepatitis C virus variant found in an infant born to a mother with multiple variants. *J Virol* 67:4365-4368, (1993).

Wejstal R, Norcans R, Weiland O, et al.

Lymphocytes subsets and B2- microglobulin expression in chronic hepatitis C: Effect of interferon alpha treatment. *Clinical Exp Immunol* 87:340-345 (1992).

Weston S and Martin P.

Serological and Molecular testing in viral hepatitis: An update. *Can J Gastroenterol* 15(3):177-184,(2001).

Wheless LL, Coon JS, Cox C, Deitch AD, et al.

Precision of DNA flow cytometry in interinstitutional analysis. *Cytometry.* 12(5): 405-12.(1991).

Wheless LL and Kay DB.

Optics, light sources, filters and optical system. *Cytometry* 36:22 (1985).

Wilber J and Polito A,

Serological and virological diagnostic tests for hepatitis C virus infection. *Semin. Gastrointest. Dis.* 6:13, (1995).

Wood JCS,

Clinical flow cytometry instrumentation. In: Baur KD, Duque RE and shan Key TV(eds): *Clinical flow cytometry, principles and applications*. Williams and Wilkins. London Pp-79 (1993).

Yamagouchi K, Tanaka E, Higashi K, et al.

Adaptation of hepatitis C virus for persistent infection in patient with acute hepatitis. *Gastroenterology* 106:1344-1338, (1994).

Younossi ZM and MacHutchison JG.

Serological tests for HCV infection. *Vira hepat Rev*, 2:161-173, (1996).

Yuk K, Schimizu M, Aoyama S, et al.

Analysis of lymphocytes subsets in liver biopsy specimens with lymphoid follicle like structures. *Acta Hepatol Jpn* 27: 720-725, (1986).

Zaaijer HL, Vrielink H, Van Exel-Oehlers P, et al.

Confirmation of hepatitis C infection: a comparison between five Immunoblot assays. *Transfusion* 34:603-607, (1994).

Zeuzem S, Schmidt J, Lee J, et al.

Effect of interferon alfa of the dynamic of hepatitis C virus turnover in vivo. *Hepatology* 23:366, (1996).

Zhang Z, Brunner T, Carter L, et al.

Unequal death in T helper cells (Th) and the T h2 effectors: Th1, but not Th2, effectors under go rapid Fas/FsaL-mediated apoptosis. *J Exp Med* 185: 1837-1849, (1997).